Figure 6.

Efficacy of combined oncolytic virotherapy/programmed cell death protein 1 (PD1) blockade therapy is dose dependent. (A) Schematic diagram of experimental design. C57/B6 mice were injected subcutaneously with B16/F10 cells. Once tumors reached ~25 mm², animals were either mock treated or treated with three intratumorous injections of 1×10⁷, 1×10⁶, or 1×10⁵ foci forming units (FFU) of myxoma virus (MYXV) (n=10+/group). Animals were subsequently given intraperitoneal injections of PD1-blocking antibody and monitored for tumor burden every other day. (B) Average tumor area (mm²) for each treatment over time. (C) Total tumor area on day 11. (D) Schematic diagram of experimental design. C57/B6 mice were injected subcutaneously with B16/F10-PDL1^-/- cells.12 Once tumors reached ~25 mm², animals were either mock treated or treated with three intratumorous injections of 1×10⁷, 1×10⁶, or 1×10⁵ FFU of MYXV (n=7+/group) and monitored for tumor burden every other day. (E) Average tumor area (mm²) for each treatment over time. (F) Total tumor area on day 11. Statistical significance was determined using unpaired Student’s t-test (***p<0.001). PDL1, programmed death-ligand 1.